Analysis of the Efficacy and Prognosis Factors of Acute Myeloid Leukemia with a Combination Therapy of Venetoclax
10.19746/j.cnki.issn1009-2137.2024.01.017
- VernacularTitle:维奈克拉联合治疗急性髓系白血病的疗效和预后因素分析
- Author:
Chong-Chong REN
1
;
Wan-Wan ZHANG
;
Ting-Kai WU
;
Bei LIU
Author Information
1. 兰州大学第一临床医学院
- Keywords:
venetoclax;
acute myeloid leukemia;
efficacy;
survival
- From:
Journal of Experimental Hematology
2024;32(1):104-111
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and prognosis factors of acute myeloid leukemia with a combination therapy of venetoclax.Methods:A retrospective analysis was performed on the clinical data of AML patients treated with a combination therapy of venetoclax from March 2020 to April 2023 in the First Hospital of Lanzhou University.The efficacy,adverse reactions and survival were observed,and the influencing factors were analyzed.Results:A total of 74 AML patients were included in this study,including 43 initially treated AML and 31 relapsed or refractory AML(R/R AML).The median age of 43 initially treated AML patients was 65 years old,the composite complete remission(cCR)rate was 67.4％(29/43),the objective response rate(ORR)was 72.1％(31/43),and the median overall survival(OS)was 17.3 months.The median age of 31 R/R AML patients was 51 years old,with a cCR rate of 38.7％(12/31),an ORR of 58.1％(18/31),and a median OS of 7.1 months.Sex,the blood cell count before VEN,gene mutation and prognosis stratification were related to whether to obtain cCR.Failure to obtain cCR was an independent risk factor for adverse outcomes.Conclusion:A combination therapy of venetoclax is safe and efficacious for AML.Its efficacy and survival are affected by molecular biology,cytogenetics and other factors.
